November 05, 2015

Further refugee aid measure:

Bayer donates medicines for refugees in Turkey, Greece and Austria

Ointments, pain relievers and antibiotics worth EUR 1.5 million made available

Leverkusen, November 5, 2015 – Bayer is making drugs with a market value of just under EUR 1.5 million available free of charge to aid organizations and authorities in Turkey, Greece and Austria to treat refugees. The biggest share of the donation, which includes ointments, pain relievers and antibiotics, is to go to Turkey.

“We are delighted to be able to help with these specifically needed drugs,” said Michael König, member of the Bayer Board of Management responsible for Human Resources, Technology and Innovation.

Bayer is also already implementing several programs for the integration of refugees. These include a pilot project with the Berlin Senate to introduce scientific study materials for refugee children with no knowledge of German and a foundation course providing language training and career guidance to young people.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to

For social media users:
Visit Bayer on Facebook at:
Follow Bayer on Twitter at:

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.